GoodRx Holdings (GDRX) Common Equity (2019 - 2026)

GoodRx Holdings' Common Equity history runs 8 years deep, the most recent figure standing at $622.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 4.95% year-over-year to $622.0 million; the TTM figure through Mar 2026 stood at $622.0 million (down 4.95% YoY), while the FY2025 annual figure was $616.3 million, down 14.96% from the prior year.
• Common Equity came in at $622.0 million for Q1 2026 at GoodRx Holdings, up from $616.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $895.4 million in Q2 2023 to a low of $600.7 million in Q3 2025.
• A 5-year average of $731.3 million and a median of $724.7 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity advanced 11.78% in 2023 and slipped 25.24% in 2024, its largest moves.
• GoodRx Holdings' Common Equity stood at $814.8 million in 2022, then dropped by 6.49% to $762.0 million in 2023, then slipped by 4.9% to $724.7 million in 2024, then decreased by 14.96% to $616.3 million in 2025, then rose by 0.93% to $622.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $622.0 million, $616.3 million, and $600.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison